1. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission 
Erica D. Warlick, Kristjan Paulson, Ruta Brazauskas, Xiaobo Zhong, Alan M. Miller, Bruce M. Camitta, Biju George, Bipin N. Savani, Celalettin Ustun, David I. Marks, Edmund K. Waller, Frédéric Baron, César O. Freytes, Gérard Socie, Gorgun Akpek, Harry C. Schouten, Hillard M. Lazarus, Edwin M. Horwitz, John Koreth, Jean-Yves Cahn, Martin Bornhauser, Matthew Seftel, Mitchell S. Cairo, Mary J. Laughlin, Mitchell Sabloff, Olle Ringdén, Robert Peter Gale, Rammurti T. Kamble, Ravi Vij, Usama Gergis, Vikram Mathews, Wael Saber, Yi-Bin Chen, Jane L. Liesveld, Corey S. Cutler, Armin Ghobadi, Geoffrey L. Uy, Mary Eapen, Daniel J. Weisdorf, Mark R. Litzow 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 2, Pages (February 2014)
DOI: /j.bbmt
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Comparison of survival post-transplant between AML CR1 subjects who did or did not receive pretransplant cytarabine consolidation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Comparison of post-transplant relapse incidence between AML CR1 subjects who did or did not receive pretransplant cytarabine consolidation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions